These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20844694)

  • 1. Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder.
    Cruz MP
    P T; 2010 Aug; 35(8):448-51. PubMed ID: 20844694
    [No Abstract]   [Full Text] [Related]  

  • 2. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
    Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guanfacine extended-release (intuniv) for ADHD.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):82-3. PubMed ID: 21045757
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents.
    Bello NT
    Patient Prefer Adherence; 2015; 9():877-85. PubMed ID: 26170637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Connor DF; Rubin J
    Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder.
    Kawaura K; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2014 Aug; 270():349-56. PubMed ID: 24882610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.
    Ota T; Yamamuro K; Okazaki K; Kishimoto T
    Drug Des Devel Ther; 2021; 15():1965-1969. PubMed ID: 34007156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
    Sallee FR; Eaton K
    Expert Opin Pharmacother; 2010 Oct; 11(15):2549-56. PubMed ID: 20831361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Rizzo R; Martino D
    Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
    Connor DF; Findling RL; Kollins SH; Sallee F; López FA; Lyne A; Tremblay G
    CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanfacine extended-release: in attention deficit hyperactivity disorder.
    Muir VJ; Perry CM
    Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB; Chae S; Patel A; Steinberg-Epstein R
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Connor DF; Arnsten AF; Pearson GS; Greco GF
    Expert Opin Pharmacother; 2014 Aug; 15(11):1601-10. PubMed ID: 24992513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
    Newcorn JH; Harpin V; Huss M; Lyne A; Sikirica V; Johnson M; Ramos-Quiroga JA; van Stralen J; Dutray B; Sreckovic S; Bloomfield R; Robertson B
    J Child Psychol Psychiatry; 2016 Jun; 57(6):717-28. PubMed ID: 26871297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanfacine and guanfacine extended release: treatment for ADHD and related disorders.
    Posey DJ; McDougle CJ
    CNS Drug Rev; 2007; 13(4):465-74. PubMed ID: 18078429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary-induced binge eating increases prefrontal cortex neural activation to restraint stress and increases binge food consumption following chronic guanfacine.
    Bello NT; Walters AL; Verpeut JL; Caverly J
    Pharmacol Biochem Behav; 2014 Oct; 125():21-28. PubMed ID: 25158105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.